Filtered By:
Specialty: Endocrinology
Condition: Heart Failure
Education: Study

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 271 results found since Jan 2013.

Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
ConclusionsTreatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke/TIA in persons with newly diagnosed type 2 diabetes.
Source: Acta Diabetologica - August 6, 2022 Category: Endocrinology Source Type: research

Risk of ischemic stroke after third, fourth, and sixth cranial nerve palsies in type 2 diabetes
ConclusionsPhysicians should pay more attention to manageable risk factors of ischemic stroke when diabetic patients suffer from ocular motor CN palsies.
Source: Journal of Diabetes - November 15, 2018 Category: Endocrinology Authors: Sang Jun Park, Hee Kyung Yang, Seong Jun Byun, Kyu Hyung Park, Jeong ‐Min Hwang Tags: ORIGINAL ARTICLE Source Type: research

An elevated likelihood of stroke, ischemic heart disease, or heart failure in individuals with gout: a longitudinal follow-up study utilizing the National Health Information database in Korea
ConclusionThe present findings suggest that individuals with gout in the Korean population, particularly those aged ≥ 60 years, were more likely to have stroke, ischemic heart disease, or heart failure.
Source: Frontiers in Endocrinology - August 23, 2023 Category: Endocrinology Source Type: research

Dose-dependent effect of smoking on risk of coronary heart disease, heart failure and stroke in individuals with type 1 diabetes
Conclusions/interpretationThere is a dose-dependent association between smoking and cardiovascular disease in individuals with type 1 diabetes. In men in particular, the risk of incident stroke remains high even after smoking cessation and is increased in current and former smokers independently of other risk factors.
Source: Diabetologia - November 5, 2018 Category: Endocrinology Source Type: research

Heart failure and stroke risks in users of liothyronine with or without levothyroxine compared to levothyroxine alone: A propensity score matched analysis
CONCLUSIONS: The use of LT3 was associated with increased incidence of heart failure and stroke in patients with a longer duration of LT3 use and history of thyroid cancer. Therefore, clinicians should consider the risk of heart failure and stroke in thyroid cancer patients with long-term use of LT3. These findings require confirmation in other populations.PMID:35570696 | DOI:10.1089/thy.2021.0634
Source: Thyroid : official journal of the American Thyroid Association - May 16, 2022 Category: Endocrinology Authors: Wook Yi Bo Hyun Kim Mijin Kim Jinmi Kim Myungsoo Im Soree Ryang Eun Heui Kim Yun Kyung Jeon Sang Soo Kim In Joo Kim Source Type: research

Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Diabetes Metab. 2023 Sep 5:101474. doi: 10.1016/j.diabet.2023.101474. Online ahead of print.ABSTRACTStroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present...
Source: Diabetes and Metabolism - September 7, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis
Publication date: Available online 3 September 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Natriuretic Peptides Studies Collaboration Background Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment. Methods In this individual-participant-data meta-analysis, we generated and harmoni...
Source: The Lancet Diabetes and Endocrinology - September 2, 2016 Category: Endocrinology Source Type: research

No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase ‐4 inhibitors vs therapeutic alternatives
ConclusionAlthough limited by the short treatment period, the present study suggests there is no increased short‐term risk of MI, stroke or HF with DPP‐4 inhibitors vs SUs/TZDs.
Source: Diabetes, Obesity and Metabolism - March 16, 2017 Category: Endocrinology Authors: Mugdha Gokhale, John B. Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J. Simpson, Til St ürmer Tags: ORIGINAL ARTICLE Source Type: research

Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
Diabetes Metab. 2022 Sep 25:101390. doi: 10.1016/j.diabet.2022.101390. Online ahead of print.ABSTRACTAtrial fibrillation/flutter (AF/AFL) is a common cardiac arrhythmia in patients with diabetes and is associated with an increased risk of morbidity, including ischaemic stroke and heart failure, and mortality. Different classes of glucose-lowering agents have shown distinct effects on the risk of stroke and heart failure. Their effects on cardiac arrhythmias such as AF/AFL have not been carefully investigated yet and even less their possible relationship with classical complications such as stroke and heart failure. The pre...
Source: Diabetes and Metabolism - September 28, 2022 Category: Endocrinology Authors: Andr é J Scheen Source Type: research

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Publication date: Available online 13 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan Background The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown....
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Incidence of adverse cardiovascular events in type  2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
ConclusionsThe incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial.
Source: Journal of Diabetes Investigation - January 29, 2021 Category: Endocrinology Authors: Shun Kohsaka, Hiraku Kumamaru, Shiori Nishimura, Satoshi Shoji, Eiji Nakatani, Nao Ichihara, Hiroyuki Yamamoto, Yoshiki Miyachi, Hiroaki Miyata Tags: Original Article Source Type: research